Generic Weight Loss Drugs Boosted by UK Approval for Biocon
- Firm got nod for first copies of anti-obesity drug liraglutide
- Firm has 15 other peptide formulations in the pipeline: CEO
Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here.
Biocon Ltd. is pivoting to anti-obesity therapies as patents for the blockbuster medications start to expire, unleashing a wave of generic supply for the global weight-loss market that’s expected to touch $100 billion by 2030.